You can view the research column published every month by SMC Laboratories.
2025.02.02
Interesting relevance between liver cancer patients and our cancer mouse model
Do you have any interest in liver cancer, hepatocellular carcinoma (HCC), or doing research about HCC? We hope…
READ MORE
2025.02.02
STAM mice develop NASH-derived hepatocarcinoma
Last year, the following article was even published in Nature Reviews Gastroenterology & Hepatology. Globa…
READ MORE
2025.02.02
Combination Therapies for NASH
It is now accepted that many factors are involved in exacerbating the NASH pathophysiology such as lipotoxicit…
READ MORE
2025.02.02
Pre-clinical studies for NASH: CDAHFD mice model
Today, we would like to give you a brief introduction to the choline-deficient, L-amino acid-defined, high-fat…
READ MORE
2025.02.02
Case study of preclinical studies for NASH
Among our lineup is the STAM™ model, which is our proprietary model that shows a 100% progression rate from NA…
READ MORE
2025.02.02
Drug Efficacy Studies in Custom Model_ Muscular Dystrophy Mouse Model
In order to meet the diversifying needs of our clients, we often use our years of expertise conducting preclin…
READ MORE
2025.02.02
Preclinical studies for COPD research: PPE model
We would like to share with you about our Porcine pancreatic elastase (PPE)-induced pulmonary emphysema model…
READ MORE
2025.02.02
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunct…
READ MORE
2025.02.02
New drugs for chronic kidney disease are desired
Between 9 – 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, ho…
READ MORE
2025.02.02
Clinically correlated gut dysfunction in liver disease model
We would like to share with you our presentation from the 5th Korea Digestive Disease Week (KDDW 2021) (Novemb…
READ MORE
